Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LGMN | Q99538 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411298 | 0.81 | SMPD3 (0.51) | MAPTCYP1A2CYP2D6POLBGAA | |
| SCHEMBL26879467 | 0.79 | ALDH1A1 (0.49) | MAPTCYP1A2CYP2D6POLBGAA | |
| SCHEMBL31284102 | 0.79 | ALDH1A1 (0.49) | MAPTCYP1A2CYP2D6POLBGAA | |
| SCHEMBL1239129 | 0.79 | POLB (0.44) | MAPTCYP1A2CYP2D6POLBGAA | |
| SCHEMBL22121151 | 0.78 | FFAR2 (0.34) | ALDH1A1MEN1KMT2AKDM4EPIK3CA | |
| SCHEMBL2231719 | 0.78 | AURKA (0.50) | MAPTCYP1A2CYP2D6POLBL3MBTL1 | |
| SCHEMBL26602271 | 0.77 | SMPD3 (0.43) | CYP1A2CYP2D6ALDH1A1MEN1KMT2A | |
| SCHEMBL31359480 | 0.77 | SMPD3 (0.43) | CYP1A2CYP2D6ALDH1A1MEN1KMT2A | |
| SCHEMBL7865338 | 0.76 | POLB (0.44) | MAPTCYP1A2CYP2D6POLBGAA | |
| SCHEMBL2270412 | 0.76 | GAA (0.47) | MAPTCYP1A2CYP2D6POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055367-A | 5-Oxo-4, 5-dihydroimidazo [1,5-a ] quinazoline compounds as PI3K [ alpha ] inhibitors | 皮卡维森治疗学股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| WO-2025085474-A1 | 5-OXO-4,5-DIHYDROIMIDAZO[1,5-A]QUINAZOLINE COMPOUNDS AS PI3K[ALPHA] INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119654321-A | PI3K alpha inhibitors | 突触活化疗法股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2010060955-A1 | NOVEL 2-MORPHOLINO-3-AMIDO-PYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270213-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | MAPT 2573/4885CYP1A2 4561/4885CYP2D6 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.